A phase II clinical trial of neoadjuvant gemcitabine and S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma
Phase 2
Recruiting
- Conditions
- resectable and borderline resectable (BR-PV) pancreatic cancer
- Registration Number
- JPRN-UMIN000038585
- Lead Sponsor
- Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with pulmonary fibrosis or interstitial pneumonia 2) Patients with other active cancers 3) Patients who can not take medicine orally 4) Patients with severe allergies 5) Patients with watery diarrhea 6) Patients with severe co-morbid disease 7) Patients seems inadequate for this study by investigator(s)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Histological curative resection (R0 ratio)
- Secondary Outcome Measures
Name Time Method Pathological responce rate, Incident of adverse event, Overall survival, Relapse free survival